RBC Capital Maintains Underperform on Amrize, Lowers Price Target to $32
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Anthony Codling maintains Amrize (NYSE:AMRZ) with a Underperform and lowers the price target from $48 to $32.
RBC Capital analyst Anthony Codling maintains Amrize (NYSE:AMRZ) with a Underperform and lowers the price target from $48 to $32.